372P - Determination of expression of EGFR in premalignant and malignant lesions of the oral cavity and evaluating the role of Gefitinib in EGFR positive...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Head and Neck Cancers
Translational Research
Presenter Umesh Velu
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors U. Velu
  • Radiation Oncology, All India Institute of Medical Sciences, 110029 - Delhi/IN

Abstract

Background

Determination of expression of EGFR in premalignant and malignant lesions of the oral cavity and evaluating the role of Gefitinib in the same

Methods

130 Patients with premalignant and malignant lesions of oral cavity from JK cancer institute, Kanpur were selected. EGFR status evaluation was done in all the patients. Premalignant lesions over expressing EGFR were observed for transformation into malignant lesions and were given Tab Gefitinib 250 mg OD daily. Malignant lesions with over expression of EGFR were randomly divided into 2 groups first group consisted of patients who were given CCRT(cisplatin). The other group had the same regimen but with the addition of Tab Gefitinib 250 mg daily

Results

Out of 130 patients registered 53 were premalignant out of which EGFR(+) positive in 73% (39) patients. EGFR ( ++)over expression were in 8%(4)patients, EGFR negative in 18%(10) patients. 77 were malignant lesions EGFR positive in 89%(51) patients. EGFR(+)in 38%(27) of patients, EGFR( ++)in 40% (28) patients, EGFR( +++) were expressed by 11% (11) patients. EGFR negative in 11%(11 patients) 30patients(total 34) in CCRT+ gefitinib arm have shown complete response in comparison to 20patients(total 32) in CCRT arm

Conclusions

EGFR status evaluation in premalignant can be used as a screening tool for detection of transformation into malignant lesions. We can prevent this transformation by EGFR inhibitors. In malignant lesions it can be really important for the role of EGFR inhibitors .Eg Gefitinib has shown good results when combined with the conventional CCRT.

Clinical trial indentification

Legal entity responsible for the study

JK Cancer Institute, Kanpur

Funding

JK Cancer Institute

Disclosure

All authors have declared no conflicts of interest.